Goldman Sachs Maintains Buy on Viridian Therapeutics, Lowers Price Target to $31

Benzinga Newsdesk www.benzinga.com Neutral 43.4%

Neg 0% Neu 43.4% Pos 0%

Goldman Sachs analyst Richard Law maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and lowers the price target from $36 to $31.